A research team at MedUni Vienna developed a method which utilizes multi-omics and machine learning to identify prostate cancer patients for whom surgical treatment is the best option, potentially avoiding unnecessary surgery in patients with a lower risk of tumor spread.
Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT, or androgen deprivation therapy, to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence, according to a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.
